tranexamic acid has been researched along with Sinus Infections in 4 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Excerpt | Relevance | Reference |
---|---|---|
"Tranexamic acid is an antifibrinolytic that is known to reduce operative bleeding." | 2.78 | Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial. ( Chiarella, A; Côté, DW; Dziegielewski, PT; Langille, MA; Mulholland, G; Sowerby, LJ; Wright, ED, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Achour, I | 1 |
Ben Rhaiem, Z | 1 |
Thabet, W | 1 |
Jdidi, J | 1 |
Mnejja, M | 1 |
Hammami, B | 1 |
Chakroun, A | 1 |
Charfeddine, I | 1 |
Jahanshahi, J | 1 |
Hashemian, F | 1 |
Pazira, S | 1 |
Bakhshaei, MH | 1 |
Farahani, F | 1 |
Abasi, R | 1 |
Poorolajal, J | 1 |
Alimian, M | 1 |
Mohseni, M | 1 |
Langille, MA | 1 |
Chiarella, A | 1 |
Côté, DW | 1 |
Mulholland, G | 1 |
Sowerby, LJ | 1 |
Dziegielewski, PT | 1 |
Wright, ED | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230] | Phase 4 | 40 participants (Actual) | Interventional | 2021-06-17 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 5.03 |
1,000mg IV Tranexamic Acid | 4.82 |
Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 4.47 |
1,000mg IV Tranexamic Acid | 3.89 |
Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 2.93 |
1,000mg IV Tranexamic Acid | 2.29 |
Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 2.12 |
1,000mg IV Tranexamic Acid | 1.44 |
Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 1.32 |
1,000mg IV Tranexamic Acid | 1.15 |
Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 1.36 |
1,000mg IV Tranexamic Acid | 0.76 |
Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7
Intervention | score on a scale (Mean) |
---|---|
Normal Saline | 0.97 |
1,000mg IV Tranexamic Acid | 0.72 |
Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
PACU | Follow-up visit | Follow-up phone call | |
1,000mg IV Tranexamic Acid | 0 | 1 | 2 |
Normal Saline | 0 | 0 | 2 |
Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7
Intervention | score on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | Postoperative day 5 | Postoperative day 6 | Postoperative day 7 | |
1,000mg IV Tranexamic Acid | 4.56 | 2.09 | 0.76 | 0.40 | 0.29 | 0.28 |
Normal Saline | 5.16 | 3.03 | 1.74 | 1.11 | 0.99 | 0.80 |
4 trials available for tranexamic acid and Sinus Infections
Article | Year |
---|---|
The Effect of Topical Tranexamic Acid in Endoscopic Sinus Surgery: A Triple Blind Randomized Clinical Trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Endoscopy; Humans; Sinusitis; Tr | 2023 |
Effect of topical tranexamic acid on bleeding and quality of surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple blind randomized clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Chronic D | 2014 |
The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Endoscopy; Female; Hospit | 2011 |
Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Chemotherapy, | 2013 |